A major multinational client has a number of high value sterile products, mostly cutting edge oncology treatments, that contribute significantly to the business.  However the products are made in only one location.  The board asked what the standby plan was in the event that the existing manufacturing site was compromised.  A review of potential manufacturing centres for technically complex, valuable products within Europe was commissioned.  The size of a facility and costs were calculated by STC.

In parallel the alternative of using contractors was explored.